Starpharma Holdings Limited
SPHRY
Price:
$4.6
Market Cap:
$294.65M
Starpharma Holdings Limited is an Australian biopharmaceutical company dedicated to advancing and marketing its proprietary dendrimer technology across global pharmaceutical, life-science, and other sectors. Among its current offerings are VivaGel, a non-antibiotic treatment designed for the management and prevention of bacterial vaginosis, alongside the antiviral VivaGel condom and VIRALEZE antiviral nasal spray. Furthermore, the company's extensive pipeline heavily features its DEP dendrimer drug delivery system, which includes several oncology candidates such as DEP docetaxel, DEP cabazitaxel, and DEP irinotecan, all currently undergoing Phase II clinical trials for various cancers. Addit...[Read more]
Industry
Biotechnology
IPO Date
2007-05-04
Stock Exchange
OTC
Ticker
SPHRY
PE Ratio
[-76.67]
ROE
[-15.96%]
Current Ratio
[5.26]
Dividend Yield
[0%]
Enterprise Value
[277.19M]
Dividend History
The ROE as of June 2026 (TTM) for Starpharma Holdings Limited (SPHRY) is -15.96%
According to Starpharma Holdings Limited’s latest financial reports and current stock price. The company's current ROE is -15.96%. This represents a change of -3.93% compared to the average of -16.62% of the last 4 quarters.
Starpharma Holdings Limited (SPHRY) Historical ROE (quarterly & annually)
How has SPHRY ROE performed in the past?
The mean historical ROE of Starpharma Holdings Limited over the last ten years is -35.94%. The current -15.96% ROE has changed -55.58% with respect to the historical average. Over the past ten years (40 quarters), SPHRY's ROE was at its highest in in the December 2025 quarter at 6.36%. The ROE was at its lowest in in the June 2020 quarter at -28.14%.
Average
-35.94%
Median
-33.50%
Minimum
-52.58%
Maximum
-19.30%
Starpharma Holdings Limited (SPHRY) ROE by Quarter and Year
Discovering the peaks and valleys of Starpharma Holdings Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 81.07%
Maximum Annual ROE = -19.30%
Minimum Annual Increase = -42.08%
Minimum Annual ROE = -52.58%
| Year | ROE | Change |
|---|---|---|
| 2025 | -52.58% | 81.07% |
| 2024 | -29.04% | -35.35% |
| 2023 | -44.92% | 34.56% |
| 2022 | -33.38% | 5.39% |
| 2021 | -31.67% | -32.40% |
| 2020 | -46.86% | 39.36% |
| 2019 | -33.62% | 74.16% |
| 2018 | -19.30% | -22.63% |
| 2017 | -24.95% | -42.08% |
| 2016 | -43.08% | -14.62% |
Starpharma Holdings Limited (SPHRY) Average ROE
How has SPHRY ROE performed in the past?
The current ROE of Starpharma Holdings Limited (SPHRY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-42.18%
5-year avg
-38.32%
10-year avg
-35.94%
Starpharma Holdings Limited (SPHRY) ROE vs. Peers
How is SPHRY’s ROE compared to its peers?
Starpharma Holdings Limited’s ROE is greater than Imugene Limited (-134.65%), greater than Satellos Bioscience Inc. (-51.42%), greater than IXICO plc (-16.18%), greater than Alterity Therapeutics Limited (-30.19%), greater than Paradigm Biopharmaceuticals Limited (-265.55%), greater than Poolbeg Pharma PLC (-55.47%), greater than BioStem Technologies, Inc. (-47.03%), greater than Nicox S.A. (-51.16%), greater than Kintor Pharmaceutical Limited (-98.57%), less than BioSyent Inc. (22.05%),
| Company | ROE | Market cap |
|---|---|---|
| -134.65% | $35.35M | |
| -51.42% | $96.62M | |
| -16.18% | $6.51M | |
| -30.19% | $11.96M | |
| -265.55% | $65.01M | |
| -55.47% | $64.80M | |
| -47.03% | $70.55M | |
| -51.16% | $30.94M | |
| -98.57% | $160.37M | |
| 22.05% | $113.70M |
Build a custom stock screener for Starpharma Holdings Limited (SPHRY) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Starpharma Holdings Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Starpharma Holdings Limited (SPHRY) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Starpharma Holdings Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Starpharma Holdings Limited's ROE?
How is the ROE calculated for Starpharma Holdings Limited (SPHRY)?
What is the highest ROE for Starpharma Holdings Limited (SPHRY)?
What is the 3-year average ROE for Starpharma Holdings Limited (SPHRY)?
What is the 5-year average ROE for Starpharma Holdings Limited (SPHRY)?
How does the current ROE for Starpharma Holdings Limited (SPHRY) compare to its historical average?